SynoCare

Nanjing Synnocare Pharmaceutical Technology is a clinical-stage biotechnology company headquartered in Nanjing, China, specializing in the discovery and development of innovative small molecule therapeutics for oncology and autoimmune diseases. The company utilizes its proprietary AI for Omics platform, which integrates artificial intelligence with multi-omics data to identify novel synthetic lethal targets and RNA-targeting drug candidates. Synnocare's pipeline features several programs, including TNK01, TNK02, and TNK03, which focus on synthetic lethality for solid tumors and hematological malignancies, as well as TNK04 and TNK05, which target RNA for cancer and inflammatory conditions like Crohn's disease and rheumatoid arthritis. By combining advanced computational tools with deep biological insights, Synnocare aims to develop first-in-class and best-in-class medicines to address significant unmet medical needs globally.